Demographic Profile, Treatment Pattern, and Outcome of Recurrent/ Metastatic Soft Tissue Sarcoma: A Single-Center Experience from Eastern India
Indian Journal of Medical and Paediatric Oncology · 01.02.2026 · 47 (01) · A01-A58
DOI: 10.1055/s-0046-1818482 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Medical and Paediatric Oncology, erschienen am 01.02.2026. Verfasst von Raghuram Mahishi und 6 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Soft tissue Sarcomas (STSs) heterogeneous group of aggressive malignancy with diverse histology. Although large scale prospective data are lacking, several histology and molecular driven approaches reported in literature. Here we aim to report the pattern of care, response and survival outcome of recurrent/metastatic STSs treated at our institute. Materials and Methods: This is a single-center retrospective study at Tata Medical Center, Kolkata. Consecutive patients with recurrent/metastatic STSs treated between 2018 and 2024 were included. Demographic profiles, treatment details and outcomes data were captured from electronic medical records of hospital till July 2024. Those who were treated with curative intent initially and later developed recurrent/ metastatic were also included in this study.
Results
Out of 83 screened patients, 49 patients were eligible for analysis with a median age of 67 years (range 24–72), majority being males (51%) with advanced/metastatic (57%) diseases. Most common site was axial (83.7%) compared to extremities (6.3%). Leiomyosarcoma (65.3%) followed by Liposarcoma (34.7%) was common histology, 18% having grade 3 tumor with 26% positive for MDM2 mutation. Most common site of distant metastases was lung (59.2%). Debulking surgery was performed in 51% of cases. Adriamycin was most commonly (41%) used systemic therapy followed by pazopanib (25%) and palbociclib (20%). The best response to first line therapy was stable disease (41%) followed by partial response (12%). The most common second and subsequent lines of therapies were pazopanib and adriamycin. With a median follow-up of 22 months; median progression free survival was 29 months (95% CI: 5.5–52.41) with median overall survival of 91 months (95% CI: 22.37–159.62).
Conclusions
Although retrospective in nature with small sample size, this study demonstrated potential therapeutic implication and remarkable survival outcome of recurrent/metastatic STSs treated at a single center from eastern India. Publication History Article published online: 20 February 2026 © 2026. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
Zitieren
APA
Mahishi, R., Roy, S., Biswas, B., Bhattacharjee, A., Sadhukhan, S., Seth, S., & Bhattacharya, S. (2026). Demographic Profile, Treatment Pattern, and Outcome of Recurrent/ Metastatic Soft Tissue Sarcoma: A Single-Center Experience from Eastern India. Indian Journal of Medical and Paediatric Oncology, 47(01), A01-A58. https://doi.org/10.1055/s-0046-1818482
Vancouver
Mahishi R, Roy S, Biswas B, Bhattacharjee A, Sadhukhan S, Seth S, et al. Demographic Profile, Treatment Pattern, and Outcome of Recurrent/ Metastatic Soft Tissue Sarcoma: A Single-Center Experience from Eastern India. Indian Journal of Medical and Paediatric Oncology. 2026;47(01):A01-A58. doi:10.1055/s-0046-1818482
BibTeX
@article{Mahishi2026,
author = {Mahishi, Raghuram and Roy, Somnath and Biswas, Bivas and Bhattacharjee, Arnab and Sadhukhan, Susmita and Seth, Soham and Bhattacharya, Sayanika},
title = {Demographic Profile, Treatment Pattern, and Outcome of Recurrent/ Metastatic Soft Tissue Sarcoma: A Single-Center Experience from Eastern India},
journal = {Indian Journal of Medical and Paediatric Oncology},
year = {2026},
volume = {47},
number = {01},
pages = {A01--A58},
doi = {10.1055/s-0046-1818482}
}
EUVIMED